Tower Research Capital (TRC)’s Boundless Bio BOLD Stock Holding History

Tower Research Capital (TRC)’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.61K	Sell	2,371 -3,432	-59%	-$4.01K	﹤0.01%	4445
2025 Q4	$6.96K	Buy	5,803 +3,210	+124%	+$4K	﹤0.01%	4039
2025 Q3	$3.19K	Sell	2,593 -3,479	-57%	-$4.01K	﹤0.01%	4536
2025 Q2	$6.13K	Sell	6,072 -346	-5%	-$460	﹤0.01%	4129
2025 Q1	$9.69K	Buy	6,418 +2,323	+57%	+$4.82K	﹤0.01%	3743
2024 Q4	$11.9K	Buy	4,095 +1,190	+41%	+$3.47K	﹤0.01%	3672
2024 Q3	$10.1K	Sell	2,905 -368	-11%	-$1.33K	﹤0.01%	3800
2024 Q2	$12.7K	Buy	+3,273	New	+$31.3K	﹤0.01%	4020

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Tower Research Capital (TRC)'s BOLD Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Boundless Bio (BOLD) stake by 59% in Q1 2026, selling an estimated $4.01K and leaving 2,371 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #4445.

Tower Research Capital (TRC) first reported a position in BOLD in Q2 2024 and has held it in 8 quarters since. The position peaked at $12.7K in Q2 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

Tower Research Capital (TRC) held 2,371 shares of Boundless Bio worth $2.61K as of Q1 2026.
Tower Research Capital (TRC) sold 3,432 Boundless Bio shares in Q1 2026, an estimated $4.01K.
Boundless Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4445 holding.
Tower Research Capital (TRC) first reported a position in Boundless Bio in Q2 2024 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s Boundless Bio position peaked at $12.7K in Q2 2024.
36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.